EP1797092A1 - Dérivés de trifluoromethyl-6-purine 2-substitués à activité antagoniste d'adénosine a3 - Google Patents

Dérivés de trifluoromethyl-6-purine 2-substitués à activité antagoniste d'adénosine a3

Info

Publication number
EP1797092A1
EP1797092A1 EP05779103A EP05779103A EP1797092A1 EP 1797092 A1 EP1797092 A1 EP 1797092A1 EP 05779103 A EP05779103 A EP 05779103A EP 05779103 A EP05779103 A EP 05779103A EP 1797092 A1 EP1797092 A1 EP 1797092A1
Authority
EP
European Patent Office
Prior art keywords
purine
trifluoromethyl
compound
methyl
phenethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05779103A
Other languages
German (de)
English (en)
Inventor
Melle Solvay Pharmaceuticals B.V. KOCH
Jacobus A.J. Den Hartog
Gerrit-Jan Solvay Pharmaceuticals B.V. KOOMEN
Martinus J. Solvay Pharmaceuticals B.V WANNER
Roelof W. Solvay Pharmaceuticals B.V FEENSTRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Priority to EP05779103A priority Critical patent/EP1797092A1/fr
Publication of EP1797092A1 publication Critical patent/EP1797092A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Definitions

  • the present invention relates to 2-substituted-6-trifluoromethyl purine derivatives as selective adenosine antagonists, in particular adenosine -A 3 receptor antagonists, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said purine derivatives.
  • the invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art.
  • the invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition.
  • the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general kno wledge in the art.
  • specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of disorders in which adenosine-A 3 receptors are involved, or that can be treated via manipulation of those receptors.
  • Adenosine receptors At present, four types of adenosine receptors have been identified and designated A 1 , A 2A , A 2B and A 3 respectively. All four belong to the super-family of seven transmembrane G-protein coupled receptors. Adenosine receptors are ubiquito us and involved in a great variety of biological processes. Thus, during the past decades the therapeutic potential of adenosine receptor ligands has resulted in a substantial research interest.
  • adenosine A 3 receptors may play a basic role in different pathologies such as inflammation and neurodegeneration, ischemic brain damage, cardiac ischemia, hypotension, ischemic heart pre-conditioning, asthma and cancer. (P.G. Baraldi et al., European Journal of Medicinal Chemistry, 38, 367-382, 2003, and references cited therein).
  • adenosine A 3 receptor antagonists have been claimed to be useful for the treatment of acute and chronic pain, inflammatory diseases including, arthritis, multiple sclerosis, asthma and psoriasis; gastro-intestinal disorders such as ulcers, inflammatory bowel disease (Crohn's disease) and ulcerative colitis; allergic responses such as eczema, atopic dermatitis and rhinitis; cardio-vascular disorders such as myocardial infarction, arrhythmias, hypertension, thrombosis, anaemia, arteriosclerosis, angina pectoris, cutaneous diseases such as urticaria, lupus erythematosus and pruritus; opthalmological disorders like glaucoma; respiratory disorders including chronic obstructive pulmonary disease, bronchitis and cystic fibrosis; central nervous system disorders including various forms of epilepsy, stroke, depression, sleep apnoea; disorders characterized by impairment of cognition and memory such
  • the available literature does not provide incentives towards the design as selective adenosine A 3 receptor antagonists of the uniquely substituted purine derivatives of the present invention , in particular with respect to the trifluoromethyl moiety at position 6 of the purine core.
  • novel compounds obtained by this new synthetic route turned out to be adenosine receptor ligands (in contrast to previo usly described 6- CF 3 derivatives), more specifically: adenosine-A 3 receptor selective antagonists.
  • the invention relates to compounds of the general formula ( 1 ):
  • - Ri represents -tX-(CH 2 )n]m-Y, in which formula X is either NH or oxygen, n is 0, 1 , 2 or 3, m is 0 or 1 , and Y is an optionally substituted 5 - or 6-membered aromatic or non-aromatic ring, containing 0, 1 or 2 hetero -atoms selected from N, O and S, or Ri represents a nitro goup,
  • R 2 is hydrogen, d -3 -alkyl, ribose, -CH 2 -O-CO-CM-butyl or aryl-(Ci -3 )alkyl,
  • R 3 represents hydrogen, halogen, NH 2 , -NH-(Ci -6 )alkyl, -N-di(Ci -6 )alkyl, -NH-cyclo(C 3-8 )alkyl, C 2-4 -alkenyl(hetero)aryl or C 2-4 -alkynyl(hetero)aryl, of which the hetero-atoms are selected from N, O, and S, and which (hetero)aryl groups may be optionally substituted, or R 3 represents an optionally substituted 5- or 6- membered aromatic or non -aromatic ring, containing 0, 1 or 2 hetero-atoms selected from nitrogen, oxygen and sulphur,
  • Such compounds are new and are adenosine-A 3 receptor antagonists.
  • the invention relates to racemates, mixtures of diastereomers as well as the individual stereoisomers of the compounds having formula (1).
  • the invention also relates to the E isomer, Z isomer and E/Z mixtures of compounds having formula (1).
  • E isomer Z isomer
  • E/Z mixtures of compounds having formula (1) Throughout this specification the generally accepted atom numbering system of the purine skeleton is used:
  • Ci_ 3 -alkyl' means 'methyl, ethyl, n-propyl or isopropyl'.
  • Optionally substituted' means that a group may or may not be further substituted by one or more groups selected from alkyl, alkenyl, alkynyl, aryl, fluoro, chloro, bromo, hydroxyl, alkyloxy, alkenyloxy, aryloxy, acyloxy, amino, alkylamino, dialkylamino, arylamino, thio, alkylthio, arylthio, cyano, oxo, nitro, acyl, amido, alkylamido, dialkylamido, carboxyl, or two optional substituents may together with the carbon atoms to which they are attached form a 5 - or 6-membered aromatic or non -aromatic ring containing 0, 1 or 2 heteroatoms selected from nitrogen,
  • 'alkyl' means d -3 -alkyl
  • 'alkenyl' means Ci -3 -alkenyl
  • 'alkynyl' means Ci -3 -alkynyl
  • 'acyl' means Ci -3 -acyl and 'aryl' means furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1 ,3,5-triazynyl, phenyl, indazolyl, indolyl, indolizinyl, isoindolyl, benzi[b]furanyl, benzo[b]thiophenyl, benz -imidazolyl, benzthiazoly
  • Optional substituents may themselves bear additional optional substituents.
  • Preferred optional substituents include Ci -3 alkyl such as for example methyl, ethyl, and trifluoromethyl, fluoro, chloro, bromo, hydroxyl, C i -3 alkyloxy such as for example methoxy, ethoxy and trifluoromethoxy, and amino.
  • Prodrugs are therapeutic agents which are inactive per se but are transformed into one or more active metabolites.
  • Prodrugs are bioreversible derivatives of drug molecules used to overcome some barriers to the utility of the parent drug molecule. These barriers include, but are not limited to, solubility, permeability, stability, presystemic metabolism and targeting limitations (Medicinal Chemistry: Principles and Practice, 1994, ISBN 0-85186-494-5, Ed.: F. D. King, p. 215; J. Stella, "Prodrugs as therapeutics", Expert Opin. Ther. Patents, 14(3), 277-280, 2004; P. Ettmayer et al., "Lessons learned from marketed and investigational prodrugs", J.Med.Chem., 47, 2393-2404, 2004).
  • Pro-drugs i.e. compounds which when administered to humans by any known route, are metabolised to compounds having formula (1), belong to the invention.
  • this relates to compounds with primary or secondary amino or hydroxy groups.
  • Such compounds can be reacted with organic acids to yield compounds having formula (1) wherein an additional group is present which is easily removed after administration, for instance, but not limited to amidine, enamine, a Mannich base, a hydroxyl -methylene derivative, an O-(acyloxymethylene carbamate) derivative, carbamate, ester, amide or enami none.
  • the invention particularly relates to compounds of formula (1) in which :
  • - Ri represents -
  • R 2 represents hydrogen, methyl, ribose or -CH 2 -O-CO-CM-butyl
  • R 3 represents hydrogen, halogen, -NH-cyclopentyl, ethenylphenyl or ethynylphenyl, which phenyl groups may be optionally substituted with a CF 3 group, or R 3 represents an optionally substituted 5- or 6-membered aromatic or non-aromatic ring, containing 0, 1 or 2 hetero -atoms selected from nitrogen, oxygen and sulphur, and tautomers, stereoisomers, prodrugs and salts thereof.
  • the invention relates to compounds of formula (1) in which
  • - Ri represents -[X-(CH 2 ) n ] m -Y, in which formula X is either NH or oxygen, n is 1 or 2, m is 0 or 1 , and Y is an optionally hydroxylated 6-membered aromatic or non- aromatic ring, containing 0 or 1 N-atoms, - R 2 represents hydrogen, methyl, ribose or -CH 2 -O-CO-CM-butyl,
  • R 3 represents hydrogen, halogen, -NH-cyclopentyl, ethenylphenyl or ethynylphenyl, which phenyl groups may be optionally substituted with a CF 3 group, or R 3 represents an optionally substituted 5- or 6-membered aromatic or non-aromatic ring, containing 0, 1 or 2 hetero -atoms selected from nitrogen, oxygen and sulphur, and tautomers, stereoisomers, prodrugs and salts thereof.
  • - Ri represents -[X-(CH 2 ) n ] m -Y, in which formula X is NH, n is 1 or 2, m is 1 , and Y is an optionally hydroxylated phenyl group, - R 2 represents hydrogen, ribose or -CH 2 -O-CO-O-£-butyl,
  • R 3 represents hydrogen, and tautomers, stereoisomers, prodrugs and salts thereof.
  • BocOM -CH 2 -O °
  • the N9 position can be functionalised with different alkyl or arylalkyl groups via standard alkylation or Mitsunobu conditions.
  • these compounds can be further functionalised by adding nucleophiles.
  • Palladium catalysed coupling procedures (Sonogashira, StNIe, Suzuki, Buchwald -Hartwig) allow for a broad range of carbon and heteroatom nude ophiles that can be introduced on the 8 position of the halo-purines.
  • the present invention therefore also relates to a process for the preparation of compounds as described above, comprising the steps of:
  • R 1 has the meanings as given in claim 1, and,
  • the trifluoromethylation step (a) is preferably carried out by adding CF 3 TMS to a suspenstion of the compound of formula (3) and CsF in dry THF.
  • the nucleophilic substitution reaction on compound (4) is preferably carried out by dissolving the compound with the chosen amine in the presence of triethylamine.
  • the reaction (c2) is preferably performed with trifluoroacetic acid.
  • the strong base in reaction (c3) is preferably MeONa in metha nol.
  • the alkylation reaction (d) of the compound of formula (6) can be performed by standard alkylation procedures or under Mitsunobu conditions.
  • the halogenation reaction (e) is preferably carried out by cooling the solution of the compound with formula (7) in THF followed by addition of n-BuLi and Br 2 or I 2 .
  • reaction (f) is performed by standard procedures, in case of an alkylation the reaction is preferably performed by Pd coupling procedure.
  • salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
  • a suitable acid for instance an inorganic acid such as hydrochloric acid, or with an organic acid.
  • the compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid carrier material.
  • the pharmaceutical compositions of the invention may be administered enterally, orally, parenterally (intramuscularly or intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders, tablets, capsules (including microcapsules), ointments (creams or gel) or suppositories.
  • Suitable excipients for such formulations are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances.
  • auxiliary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol.
  • Compounds of the present invention are generally administered as pharmaceutical compositions which are important and novel embodiments of the invention because of the presence of the compounds, more particularly specific compounds disclosed herein.
  • Types of pharmaceutical compositions that may be used include but are not limited to tablets, chewable tablets, capsules, solutions, parenteral solutions, suppositories, suspensions, and other types disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art.
  • the invention also includes the preparation or manufacture of said pharmaceutical compositions.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention.
  • Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration.
  • adenosine-A 3 receptor antagonistic properties of the compounds of the invention were determined using the methods outlined below.
  • Affinity of the compounds for human adenosine-A 3 receptors was determined using the receptor binding assay described by CA. Salvatore et al.: "Molecular cloning and characterization of the human A 3 adenosine receptor", Proc. Natl. Acad. Sci. USA, 90, 10365-10369, 1993. Briefly, membrane preparations were obtained from human recombinant (HEK 293) cells in which the human adenosine-A 3 receptor was stably expressed. Membranes were incubated at 22 0 C for 90 minutes with [ 125 I]-AB-MECA in the absence or presence of testcompounds in a concentration range from 10 ⁇ M down to 0.1 nM, diluted in a suitable buffer.
  • a stable monoclonal hA3-Aequorin cell line was provided by Euroscreen.
  • the coding region encoding the human Adenosine A3 receptor was amplified by polymerase chain reaction (PCR), using human lung cDNA as template.
  • the PCR product was ligated in the expression vector pEFIN3 (Invitrogen), and the complete sequence of the insert was then established. Sequencing revealed a complete identity with the sequence published by Salvatore, CA. et al. (Ace. Number GenBank: L22607).
  • the expression plasmid containing the coding sequence of the human Adenosine A3 receptor was transfected in CHO-K1 cells stably expressing mitochondrially targetted Aequorin and G ⁇ 16.
  • Resistant clones were selected in the presence of 400 ⁇ g/ml G418 and isolated by limiting dilution. The clone with the best response to 2 -CI-IB- MECA was selected for further work.
  • the hA3 -Aequorin cells express mitochondrially targetted apo-Aequorin. Cells have to be loaded with coelenterazine, in order to reconstitute active Aequorin. After binding of agonists to the hA3 receptor, the intracellular calcium concentration increases, which leads to a luminescent response.
  • Binding of calcium to the apo-Aequorin/coelenterazine complex leads to an oxidation reaction of coelenterazine, which results in the production of apo -Aequorin, coelenteramide, CO 2 and light ( ⁇ ma ⁇ 469 nm). This luminescent response is dependent on the agonist concentration.
  • Adenosine receptor subtype selectivity of the compounds of the invention was determined using the methods described below In vitro affinity for human adenosine-Ai receptors
  • Affinity of the compounds for human adenosine ⁇ receptors was determined using the receptor binding assay described by A. Townsend-Nicholson and P. R. Schofield (Biol. Chem., 269, 2373, 1994), using human recombinant receptors expressed in CHO cells, and [ 3 H]DPCPX as radioligand.
  • Affinity of the compounds for human adenosine-A 2A receptors was determined using the receptor binding assay described by D. R. Luthin et al., (MoI. Pharmacol., 47, 307, 1995), using human recombinant receptors expressed in HEK-293 cells, and [ 3 H]CGS 21680 as radioligand.
  • Affinity of the compounds for human adenosine-A 2 B receptors was determined using the receptor binding assay described by J. H. Stehle et al. (Mo/. Endocrinol., 6, 384, 1992), using human recombinant receptors expressed in HEK-293 cells, and [ 3 H]MRS 1754 as radioligand.
  • the compounds of the invention have affinity for adenosine -A 3 receptors in the binding assay described above, and were shown to be antagonists in the functional assay, also described above. These properties make them useful in the treatment of disorders in which adenosine-A 3 receptors are involved, or that can be treated via manipulation of these receptors.
  • the affinity of the compounds of the invention for adenosine A 3 receptors was determined as described above. From the binding affinity measured for a given compound of formula (1), one can estimate a theoretical lowest effective dose. At a concentration of the compound equal to twice the measured Kj-value, nearly 100% of the adenosine A 3 receptors likely will be occupied by the compound. Converting that concentration to mg of compound per kg of patient yields a theoretical lowest effective dose, assuming ideal bioavailability. Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administere d to a higher or lower value. The dosage expediently administered is 0.001 - 1000 mg/kg, preferably 0.1 -100 mg/kg of patient's bodyweight.
  • treatment refers to any treatment of a mammalian, preferably human, condition or disease, and includes: (1) preventing the disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it, (2) inhibiting the disease or condition, i.e., arresting its development, (3) relieving the disease or condition, i.e., causing regression of the condition, or (4) relieving the conditions caused by the disease, i.e., stopping the symptoms of the disease.
  • Nuclear magnetic resonance spectra ( 1 H NMR and 13 C NMR, APT) were determined in the indicated solvent using a Bruker ARX 400 ( 1 H: 400 MHz, 13 C: 100 MHz) at 300 K, unless indicated otherwise.
  • 19 F NMR and 13 C NMR experiments were carried out on a Varian Inova 500 spectrometer o perating at 11.74 T (499.9 MHz for 1 H; 125.7 MHz for 13 C; 50.7 Mhz, 470.4 MHz for 19 F) using a 5 mm SW probe.
  • the spectra were determined in deuterated chloroform or dichloromethane obtained from Cambridge Isotope Laboratories Ltd.
  • Mass spectra and accurate mass measurements were performed using a JEOL JMS - SX/SX 102 A Tandem Mass Spectrometer using Fast Atom Bombardement (FAB). A resolving power of 10,000 (10% valley definition) for high resolution FAB mass spectrometry was used. Extinction coefficients were determined with a HP 8453 UV- Vis spectrophotometer.
  • Trifluoroacetic acid anhydride (3.95 ml; 28 mmol) was added dropwise to a solution of commercially available 6-chloro-9-Me-purine (3 g; 17 mmol) and tetrabutylammoniumnitrate (TBAN) (8.65 g; 28 mmol) in dry DCM (50 ml) at 0 0 C under a nitrogen atmosphere. After stirring for 1.5 h the solution was poured into 100 ml of saturated aqueous NaHCCMce (1 :1) and Et 2 O (100 ml) was added. The aqueous layer was extracted with 3 portions of 60 ml Et 2 O-CH 2 CI 2 (3:1).
  • TFAA (2.25 ml; 13 mmol) was added dropwise to a solution of 6 -chloro-9-BocOM- purine (2.84 g; 10 mmol, intermediate C) and TBAN (4.87 g; 13 mmol) in dry CH 2 CI 2 (25 ml) at 0 0 C under a nitrogen atmosphere. After stirring for 1.5 h the solution was poured into 75 ml of saturated aqueous NaHCO 3 -ice (1 :1) and Et 2 O (75 ml) was added. The aqueous layer was extracted with 3 portions of 50 ml Et 2 O-CH 2 CI 2 (3:1).
  • 6-Trifluoromethyl-9-(Tri-O-acetate-ribose)-2-nitropurine (intermediate F, 0.100 g, 0.2 mmol) was treated with morpholine (0.175 ml, 2 mmol) and triethylamine (0.2 ml) in 1ml THF. After the reaction was complete, the product was purified by flash chromatography (EA) to yield compound 2 (30 mg, 37%).
  • This compound was prepared from compound 12 (20 mg, 0.045 mmol), 2- thiopheneboronic acid (12 mg, 0.089 mmol), Pd(PPh 3 J 4 (13 mg, 0.011 mmol) and Na 2 CO 3 (51 mg, 0.179 mmol) in DME/H 2 O (6:1) (2.0 mL) by the procedure described for the preparation of 19 to give compound 14 (11 mg, 55%) as a yellow solid.
  • This compound was prepared from compound 12 (40 mg, 0.089 mmol) and E-2- phenylvinylboronic acid (26 mg, 0.179 mmol) by the procedure described for the preparation of compound 19.
  • Workup of the reaction mixture and flash chromatography (gradient: EA/PE (1 :5) - EA/PE (1 :2), 150 mL) gave, after evaporation, compound 21 (38 mg, 100%) as a red/orange oil. Yellow crystals (24 mg) were obtained after crystallization from methanol.
  • This compound was prepared from compound 12 (40 mg, 0.089 mmol) and E-2-(4- trifluoromethylphenyl)vinylboronic acid (39 mg, 0.179 mmol) by the procedure described for the preparation of compound 19.
  • flash chromatography gradient: EA/PE (1 :5) - EA/PE (1 :2), 150 mL
  • compound 24 44 mg, 100%
  • Adenosine receptor affinity data as well as functional adenosine -A 3 receptor data, obtained according to the protocols given above, are shown in the table below. All of the tested compounds have an affinity for adenosine A 3 receptors higher than that for the other adenosine receptor subpopulations. In all of the compounds investigated the affinity for adenosine A 3 receptors was shown to translate into adenosine A 3 receptor antagonism (pA 2 values ranging from 5.1 - 9.8). None of the investigated compounds showed adenosine A 3 receptor agonism in concentrations up to 10 "5 M (pEC 50 ⁇ 5.0).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés de 6-trifluorométhyl purine de substitution en 2 comme antagonistes sélectifs de l'adénosine, plus précisément des antagonistes du récepteur de l'adénosine A3; elle concerne également des procédés permettant de préparer ces composés ainsi que de nouveaux intermédiaires utilisés pour la synthèse desdits dérivés de la purine. Lesdits composés présentent la formule générale (1), dans laquelle les symboles ont la signification donnée dans le descriptif.
EP05779103A 2004-09-09 2005-09-07 Dérivés de trifluoromethyl-6-purine 2-substitués à activité antagoniste d'adénosine a3 Withdrawn EP1797092A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05779103A EP1797092A1 (fr) 2004-09-09 2005-09-07 Dérivés de trifluoromethyl-6-purine 2-substitués à activité antagoniste d'adénosine a3

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60814704P 2004-09-09 2004-09-09
EP04104344 2004-09-09
EP05779103A EP1797092A1 (fr) 2004-09-09 2005-09-07 Dérivés de trifluoromethyl-6-purine 2-substitués à activité antagoniste d'adénosine a3
PCT/EP2005/054404 WO2006027365A1 (fr) 2004-09-09 2005-09-07 Derives de 6-trifluoromethyl purine de substitution en 2 a activite antagoniste de l'adenosine a3

Publications (1)

Publication Number Publication Date
EP1797092A1 true EP1797092A1 (fr) 2007-06-20

Family

ID=34929557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05779103A Withdrawn EP1797092A1 (fr) 2004-09-09 2005-09-07 Dérivés de trifluoromethyl-6-purine 2-substitués à activité antagoniste d'adénosine a3

Country Status (5)

Country Link
EP (1) EP1797092A1 (fr)
AR (1) AR050630A1 (fr)
CA (1) CA2579302A1 (fr)
TW (1) TW200613303A (fr)
WO (1) WO2006027365A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602412D0 (en) * 2006-02-07 2006-03-15 Univ York Compounds
EP2300496A4 (fr) * 2008-07-16 2012-04-25 King Pharmaceuticals Res & Dev Méthodes de traitement de l athérosclérose
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
EP4430042A1 (fr) 2021-11-09 2024-09-18 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004217582A (ja) * 2003-01-16 2004-08-05 Abbott Japan Co Ltd ９ｈ−プリン誘導体
US7163928B2 (en) * 2003-02-03 2007-01-16 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006027365A1 *

Also Published As

Publication number Publication date
TW200613303A (en) 2006-05-01
AR050630A1 (es) 2006-11-08
CA2579302A1 (fr) 2006-03-16
WO2006027365A1 (fr) 2006-03-16

Similar Documents

Publication Publication Date Title
US7371737B2 (en) 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity
EP3572412B1 (fr) Dérivé de pyridine en tant qu'inhibiteur d'ask1, son procédé de préparation et son utilisation
KR102081272B1 (ko) Janus 키나아제 억제제
TWI483947B (zh) 胺甲醯吡啶酮ｈｉｖ整合酶抑制劑之合成及中間體
KR20140022114A (ko) 유기 화합물
CN113365631B (zh) 布鲁顿酪氨酸激酶抑制剂
EP1797092A1 (fr) Dérivés de trifluoromethyl-6-purine 2-substitués à activité antagoniste d'adénosine a3
EP3737679B1 (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
CN110857300B (zh) 一类稠环三氮唑类化合物、制备方法和用途
JP2018515559A (ja) ヒドロキシプリン類化合物及びその応用
WO2008027585A2 (fr) Pyrrolo[3,2-d]pyrimidines antagonistes sélectifs des récepteurs de l'adénosine a2b
CN115996727A (zh) 新型Rho相关蛋白激酶抑制剂的制备方法和此制备方法中的中间体
EP3719013B1 (fr) Dérivé de pyrimidine sulfamide, son procédé de préparation et son utilisation médicale
JP5781537B2 (ja) ヒスタミンｈ４受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体
EP1791841A1 (fr) Dérivés de 1-deaza purine 2-substitués à activité modulatrice du recepteur d'adénosine
CN116354988A (zh) 四环类化合物及其医药用途
CN117460720A (zh) 一种杂环烷基类化合物的制备方法、其中间体及其应用
ITMI990146A1 (it) Processo per la preparazione di derivati alchimercaptometilergolinici
CN107614501B (zh) 羟基嘌呤类化合物及其应用
Zecchini et al. A new route to N2‐and N3‐substituted‐2, 3‐diaminopyridines. Synthesis of 1‐and 3‐alkoxycarbonyl‐v‐triazolo [4, 5‐b] pyridines
EP3589615A1 (fr) Dérivés de pyridyle utilisés en tant qu'inhibiteurs de bromodomaine
JPH02289574A (ja) 選択的なアデノシンレセプター化合物
PT2137202T (pt) Processo para a síntese de ib-meca
MINEO et al. Studies on Heterocyclic Compounds. XXXII. Synthesis of 8-Substituted Theophyllines from 6-Amino-5-benzylideneamino-1, 3-dimethyluracils with Nickel Peroxide
NZ256195A (en) 2-substituted adenosine derivatives and pharmaceutical compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

17Q First examination report despatched

Effective date: 20070712

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20070410

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT HEALTHCARE PRODUCTS B.V.

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120403